Targeting integrin α2 as potential strategy for radiochemosensitization of glioblastoma
Authors:
- 11 October 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (4) , 648-661
Abstract
Glioblastoma (GBM) is a fast-growing primary brain tumor characterized by high invasiveness and resistance. This results in poor patient survival. Resistance is caused by many factors, including cell-extracellular matrix (ECM) interactions. Here, we addressed the role of adhesion protein integrin α2, which we identified in a high-throughput screen for novel potential targets in GBM cells treated with standard therapy consisting of temozolomide (TMZ) and radiation. In our study, we used a range of primary/stem-like and established GBM cell models in vitro and in vivo. To identify regulatory mechanisms, we employed high-throughput kinome profiling, Western blotting, immunofluorescence staining, reporter, and activity assays. Our data showed that integrin α2 is overexpressed in GBM compared to normal brain and, that its deletion causes radiochemosensitization. Similarly, invasion and adhesion were significantly reduced in TMZ-irradiated GBM cell models. Furthermore, we found that integrin α2-knockdown impairs the proliferation of GBM cells without affecting DNA damage repair. At the mechanistic level, we found that integrin α2 affects the activity of activating transcription factor 1 (ATF1) and modulates the expression of extracellular signal-regulated kinase 1 (ERK1) regulated by extracellular signals. Finally, we demonstrated that integrin α2-deficiency inhibits tumor growth and thereby prolongs the survival of mice with orthotopically growing GBM xenografts. Taken together our data suggest that integrin α2 may be a promising target to overcome GBM resistance to radio- and chemotherapy. Thus, it would be worth evaluating how efficient and safe the adjuvant use of integrin α2 inhibitors is to standard radio(chemo)therapy in GBM.Keywords
Funding Information
- Wilhelm Sander Foundation
- Europäischer Fonds für regionale Entwicklung (100066308)
This publication has 39 references indexed in Scilit:
- Glioblastoma Multiforme Therapy and Mechanisms of ResistancePharmaceuticals, 2013
- An integrated transcriptomic and computational analysis for biomarker identification in gastric cancerNucleic Acids Research, 2010
- 4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in TumorsCancer Cell, 2010
- Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators by oligonucleotide microarray analysisBMC Cancer, 2009
- A Human Protein Atlas for Normal and Cancer Tissues Based on Antibody ProteomicsMolecular & Cellular Proteomics, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- ATF1 Phosphorylation by the ERK MAPK Pathway Is Required for Epidermal Growth Factor-induced c-jun ExpressionJournal of Biological Chemistry, 2002
- MSK1 and MSK2 Are Required for the Mitogen- and Stress-Induced Phosphorylation of CREB and ATF1 in FibroblastsMolecular and Cellular Biology, 2002
- Specific Residues within the α2 Integrin Subunit Cytoplasmic Domain Regulate Migration and Cell Cycle Progression via Distinct MAPK PathwaysJournal of Biological Chemistry, 2001
- α2 Integrin Subunit Cytoplasmic Domain-dependent Cellular Migration Requires p38 MAPKJournal of Biological Chemistry, 2001